The document outlines recent advances in IVF technology, emphasizing improved techniques such as cytoplasmic transfer, microfluidic sperm selection, stem cell therapy for non-obstructive azoospermia, human growth hormone usage during IVF cycles, and intralipid infusion along with neupogen washes. Each advancement addresses specific reproductive challenges and aims to enhance success rates and embryo safety during the IVF process. These innovations reflect the ongoing evolution of assisted reproductive technology since the inception of IVF in 1978.

1. Recent Advances and Trends in IVF
Technology
By The Lifesciences Magazine
Trends in IVF Technology :
Since the birth of Louise Brown, the first baby born through in vitro
fertilization, in 1978, assisted reproductive technology has advanced
significantly. The success rate of in vitro fertilization (IVF) has risen
dramatically over the last four decades as a result of developments in
incubation methods, micromanipulation technology, and a general
understanding of assisted reproduction.
Thanks to developments in science and assisted reproductive technology,
we are able to provide you with cutting-edge treatment options designed to
increase your chances of having a healthy baby. Our clinic is equipped with
the following types of cutting-edge assisted reproductive technology: We
encourage you to inquire about the advantages of these cutting-edge IVF
procedures.

2. Let’s dive into Trends in IVF
Technology.
Here are the Recent Advances
and Trends in IVF Technology;
1. IVF Treatment with Cytoplasmic Transfer
Cytoplasmic transfer in vitro fertilization (IVF) is a revolutionary step
forward Trends in IVF Technology. Women of advanced maternal age,
those with known mitochondrial DNA problems, and women of advanced
maternal age who have damaged cytoplasm and mitochondria in their egg
cells may all benefit from this therapy approach.
The mitochondria, a kind of organelle located in the cytoplasm of a cell, is
essential for the cell’s survival and growth since it is responsible for
producing energy and regulating the cell’s division and growth. It’s the
“engine” that drives the cell. The offspring (child) gets exclusively maternal
mitochondrial DNA during reproduction, implying that the infant obtains no

3. mitochondrial DNA from any other source. These include Trends in IVF
Technology.
The infant will also have defective mitochondrial DNA and will have
developmental issues if the mother has mitochondrial DNA defects.
Mitochondrial DNA in the mother may become flawed for a number of
reasons, including inherited conditions and simple aging.
This technique, known as cytoplasmic transfer, involves combining the
genetic material from the egg of the recipient with the cytoplasm (the fluid
within the cell that includes essential organelles, including the
mitochondria) of a young and healthy egg donor. What this means is that
the patient’s egg cell receives a shot of healthy mitochondria, giving it a
fresh lease on life.
Problems with aged eggs’ cytoplasm and organelles may be remedied with
this technique. While cytoplasmic transfer improves the host environment in
which a patient’s own genes may flourish, it cannot reverse the effects of
aging on a patient’s genes.
Conspicuous birth abnormalities like Down syndrome and others that may
be traced back to a mother’s genes are more common among children born
to older mothers. Although cytoplasmic transfer helps the embryo grow in a
healthy setting, it cannot fix the genetic defects caused by the deterioration
of the egg’s genetic material over time. This is also Trends in IVF
Technology.
Patients over the age of 40 who have a sufficient degree of ovarian function
but who have been unsuccessful with conventional IVF/ICSI should
consider undergoing cytoplasmic IVF therapy is Trends in IVF Technology.
The success rate of employing a patient’s own eggs rises when they are
fed a better fuel source.
But because of the increased risk of genetic defects in offspring in
individuals over the age of 40, we propose that pre-implantation genetic
screening be used to check for chromosomal aneuploidies in embryos
generated using cytoplasmic transfer before embryo transfer. Please visit
our “Cytoplasmic IVF Transfer” page for more details.
2. Microfluidic Chip for Sperm Selection
One of the most significant turning points in the development of assisted
reproductive technologies was the discovery of intracytoplasmic sperm
injection (ICSI). By allowing embryologists to fertilize the eggs directly with
a hand-selected sperm cell, ICSI has drastically increased fertilization rates
compared to traditional IVF approaches,

4. Which simply involves placing the eggs and sperm in a dish and hoping the
sperm would fertilize the eggs on their own. Hundreds of thousands of men
have been able to become dads with the use of ICSI after prior IVF cycles
failed to owe to insufficient sperm parameters for fertilization.
After in vitro fertilization (ICSI), the MicroFluidic Chip has been the most
significant development in assisted reproduction. By simulating the routes
in the cervical region of the female reproductive system, the MicroFluidic
chip is able to prevent the vast majority of genetically flawed sperm from
crossing through.
One side of the chip contains the sperm sample. This is the beginning of
the sperm cells’ trip to the fallopian tubes, which is quite similar to the
cervical route. It is considered to be Trends in IVF Technology. In order to
ensure that only genetically healthy sperm cells with fertilization potential
make it to the finish line, the chip employs a series of mechanisms that
prevent damaged sperm cells from completing the race.
In other words, whereas ICSI enables the embryologist to pick the “best”
sperm cells based on appearance, the MicroFluidic chip enables the
embryologist to select the “best” sperm cells based on both morphological
and genetic traits.
Couples with male factor infertility and who have tried IVF Technology
before but had low fertilization rates or early losses that they believe were
caused by sperm DNA abnormalities may benefit from using the
MicroFluidic chip. Is one of the Great Trends in IVF Technology.
3. Stem Cell Therapy for Non-Obstructive
Azoospermia

5. Both the field of cosmetics and the field of orthopedics have recently
benefited from stem cell therapy. IVF therapies may benefit from
endometrial rejuvenation and sperm cell production thanks to the concept
of employing stem cells for the rejuvenation of the existing cell lines
(spermatogenesis) are also Trends in IVF Technology.
The stem cells may develop into sperm by being directed to become the
progenitors of germ lines. Evidence from studies shows that mesenchymal
stem cells not only aid in the expansion of cell line populations but also
help generate a positive immunological response, which boosts the
treatment’s chances of success. It is said to be Trends in IVF Technology.
Non-obstructive azoospermia is a prominent problem in male infertility. In
cases of obstructive azoospermia, surgical sperm extraction/aspiration
techniques like percutaneous endoscopic sperm aspiration (PESA) or
transcervical endoscopic sperm aspiration (TESA) can be effective in
obtaining live sperm cells, which are then used in in vitro fertilization (IVF)
treatments to fertilize the oocytes of the female partner.
In contrast, in non-obstructive azoospermia, nothing is blocking or
obstructing the sperm. No sperm cells are being produced. This may be the
result of a genetic flaw, an injury, or medical treatment (such as
chemotherapy or radiation therapy) for cancer. To date, sperm donation
has been the sole approved therapy for non-obstructive azoospermia,
regardless of the underlying etiology.

6. Recent animal experiments have revealed that mesenchymal stem cells
produced from adipose tissue may differentiate into sperm-like cells,
restoring fertility. Patient-derived mesenchymal stem cells are promising
since they have the lowest risk of undergoing malignant transformation.
This might lead to their use in the near future for restoring male fertility. For
further details, please review our article titled “Stem cell treatment for non-
obstructive azoospermia.”
4. Human Growth Hormone During IVF
Cycles
Human growth hormone was first used in IVF cycles a few years ago with
the goal of increasing the quality of the oocytes produced throughout the
cycle. Previous research had little success in seeing any effects, but a
recent study has shown that human growth hormone supplementation,
when administered at the optimal time, enhanced oocyte quality and
conception rates.
By stimulating small pre-antral follicles that would not have been stimulated
using standard ovulation induction protocols used in IVF/ICSI treatments,
starting human growth hormone not on the cycle of ovulation induction, but
earlier, has proven to positively affect the outcome of an ovulation induction
cycle.
The findings of this research led to the Food and Drug Administration
approving human growth hormone clinical trials. However, the same clinical
experiment has been made commercially accessible at North Cyprus IVF
Center as of the beginning of 2016 (despite the fact that it is only open to a
select group and results won’t be available until 2018).
Thus far, 11 individuals have been treated with HGH, and we expect to be
able to publish our own statistics by the middle of 2017. For the same price
as regular human growth hormone injections, you may take advantage of
this therapy option from us. It has been known as the Trends in IVF
Technology.
To boost yourself more in Trends in IVF Technology
5. Intralipid Infusion Therapy and Neupogen
Wash in IVF Cycles

7. To protect the embryo against NK cells, women with high natural killer cell
counts are now given an infusion of intralipids before and after embryo
transfer as part of a relatively recent development in vitro fertilization (IVF)
therapies. To avoid having the embryo destroyed because the immune
system considers it as a “foreign object,” this strategy involves dampening
the immunological response both before and after embryo transfer.
Patients who have tried many IVF cycles without success and women who
have had repeated miscarriages, which may be caused by an
overactive immune system, may benefit from intralipid infusion treatment.
Neupogen washes have mostly supplanted intralipid infusion therapy as a
treatment option as of late. It is important to note that Neupogen is a
recombinant version of G-CSF (granulocyte colony-stimulating factor). In
the reproductive system, G-CSF plays a crucial function as a chemical
messenger. A greater amount of this substance in the female body has
been linked to better embryo viability and increased IVF success, as
evidenced by clinical studies.
Using nitrogen as a subcutaneous injection plus an endometrial cavity
wash has been shown to increase endometrial lining thickness, which is
beneficial for IVF cycles. Neupogen administration at sperm-inhibiting time
points during an IVF cycle has been proven to increase pregnancy rates in
comparable trials of individuals with recurrent IVF failures.

8. However, the precise application and time gap within the cycle are of
paramount importance. Neupogen has worked similarly well for us over the
last several months, so we do advocate and utilize it, especially for people
in the older age ranges or with unexplained IVF failures. These are useful
Trends in IVF Technology.